Makary’s Exit From FDA Gives Biotech Hope ‘Circus’ Is Over

Marty Makary’s exit as head of the Food and Drug Administration is giving the biotech industry hope for stability after months of turmoil.

Makary’s departure, which was announced by President Donald Trump on Tuesday, ended his tumultuous time at the more than 16,000-person agency tasked with ensuring that Americans’ food and medicines are safe and effective. His appointment last year was initially viewed positively by biotech leaders who saw the surgeon from Johns Hopkins University School of Medicine as a less radical choice than others picked by Health Secretary Robert F. Kennedy Jr.